PharmaEssentia announced on the 2nd that it has submitted an application to the Taiwan Food and Drug Administration (TFDA) to conduct a Phase I clinical trial for its T-cell receptor (TCR-T) immunotherapy, TCRT-ESO-A2-TW, for the treatment of patients with advanced solid tumors. This marks a significant milestone for PharmaEssentia as it ventures into the field of cell therapy.
In recent years, cell therapy has rapidly emerged as a critical innovative technology for treating solid tumors. TCR-T immunotherapy works by genetically modifying a patient's T cells in vitro, enabling them to specifically recognize and attack tumor cells before being reintroduced into the patient's body for treatment. Compared to other therapies, TCR-T has a unique advantage in its ability to identify a broad range of cancer antigens within tumor cells, positioning it as a highly promising treatment for solid tumors.
In the global development of TCR-T therapies, the U.S. Food and Drug Administration (FDA) approved Adaptimmune Therapeutics' TCR-T therapy, Tecelra, in August of this year. Tecelra is used to treat adult patients with unresectable or metastatic synovial sarcoma who have previously undergone chemotherapy. Tecelra is the world’s first approved T-cell therapy for treating solid tumors and the first TCR-T therapy to be approved for market use. It also provides the first new treatment option for synovial sarcoma patients in over a decade, demonstrating the high efficacy of this approach. This breakthrough highlights the potential for TCR-T therapies to offer diverse options for cancer treatment, particularly for cancer types where traditional therapies have proven ineffective.
TCRT-ESO-A2-TW is an autologous TCR-T immunotherapy targeting solid tumors in patients who are positive for both HLA-A*02:01 and NY-ESO-1. Preliminary Phase II clinical trial data presented at the 2024 American Society of Clinical Oncology (ASCO) annual meeting has shown good safety, tolerability, and efficacy in patients with advanced soft tissue sarcoma. Under a collaborative agreement with Axis Therapeutics Limited (Axis), PharmaEssentia is conducting early-phase clinical studies of TCRT-ESO-A2-TW in Taiwan. PharmaEssentia also holds the exclusive right to negotiate licensing agreements related to TCRT-ESO-A2-TW with Axis.
PharmaEssentia noted that it has established a research and development base for T-cell therapies and cell preparation facilities at the National Biotechnology Research Park in Nangang, Taiwan. Axis is providing the necessary technology and equipment for the trials and is actively training specialized personnel.
PharmaEssentia CEO Ko-Chung Lin commented that cell therapy is revolutionizing cancer treatment. In addition to its successes in the hematologic oncology field, PharmaEssentia is now expanding into T-cell-based cancer immunotherapy. This will become one of the company's focal points for future development. The submission of this clinical trial application marks an important milestone in PharmaEssentia's journey towards innovative immunotherapies. The company aims to collaborate with leading global medical institutions and partners to continue advancing cancer treatment, ultimately benefiting more patients.
Resource (mandarin): 藥華藥申請 T 細胞受體免疫療法臨床 邁入細胞療法領域
